Host Responses to Respiratory Syncytial Virus Infection

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 Oct 28

PMID 37896776

Authors

Ayse Agac

Sophie M Kolbe

Martin Ludlow

Albert D M E Osterhaus

Robert Meineke

Guus F Rimmelzwaan

Affiliations

Soon will be listed here.

Abstract

Respiratory syncytial virus (RSV) infections are a constant public health problem, especially in infants and older adults. Virtually all children will have been infected with RSV by the age of two, and reinfections are common throughout life. Since antigenic variation, which is frequently observed among other respiratory viruses such as SARS-CoV-2 or influenza viruses, can only be observed for RSV to a limited extent, reinfections may result from short-term or incomplete immunity. After decades of research, two RSV vaccines were approved to prevent lower respiratory tract infections in older adults. Recently, the FDA approved a vaccine for active vaccination of pregnant women to prevent severe RSV disease in infants during their first RSV season. This review focuses on the host response to RSV infections mediated by epithelial cells as the first physical barrier, followed by responses of the innate and adaptive immune systems. We address possible RSV-mediated immunomodulatory and pathogenic mechanisms during infections and discuss the current vaccine candidates and alternative treatment options.

Citing Articles

Development of a general anti-viral therapeutic using cholestosome technology to exploit inhibition of intracellular viral production.

Mielnicki L, Hughes J, Irving M, McCourt M Biochem Biophys Rep. 2025; 41:101922.

PMID: 39926208 PMC: 11803885. DOI: 10.1016/j.bbrep.2025.101922.

Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus.

Shan X, Han R, Cheng X, Bing J, Qi Z, Sun S Vaccines (Basel). 2025; 13(1).

PMID: 39852872 PMC: 11769257. DOI: 10.3390/vaccines13010093.

Recombinant RSV G protein vaccine induces enhanced respiratory disease via IL-13 and mucin overproduction.

Kawahara E, Senpuku K, Kawaguchi Y, Yamamoto S, Yasuda K, Kuroda E NPJ Vaccines. 2024; 9(1):187.

PMID: 39394212 PMC: 11470036. DOI: 10.1038/s41541-024-00987-w.

The Role of the CX3CR1-CX3CL1 Axis in Respiratory Syncytial Virus Infection and the Triggered Immune Response.

Rivas-Fuentes S, Salgado-Aguayo A, Santos-Mendoza T, Sevilla-Reyes E Int J Mol Sci. 2024; 25(18).

PMID: 39337288 PMC: 11432029. DOI: 10.3390/ijms25189800.

Pathogenesis, Diagnosis, and Treatment of Infectious Rhinosinusitis.

Huang F, Liu F, Zhen X, Gong S, Chen W, Song Z Microorganisms. 2024; 12(8).

PMID: 39203531 PMC: 11357447. DOI: 10.3390/microorganisms12081690.

References

Sealy R, Surman S, Hurwitz J . CD4 T cells support establishment of RSV-specific IgG and IgA antibody secreting cells in the upper and lower murine respiratory tract following RSV infection. Vaccine. 2017; 35(20):2617-2621. PMC: 5588898. DOI: 10.1016/j.vaccine.2017.03.073. View

Simoes E . Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective. J Infect Dis. 2022; 226(Suppl 1):S1-S9. DOI: 10.1093/infdis/jiac252. View

Chirkova T, Lin S, Oomens A, Gaston K, Boyoglu-Barnum S, Meng J . CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol. 2015; 96(9):2543-2556. PMC: 4635495. DOI: 10.1099/vir.0.000218. View

Drake M, Bivins-Smith E, Proskocil B, Nie Z, Scott G, Lee J . Human and Mouse Eosinophils Have Antiviral Activity against Parainfluenza Virus. Am J Respir Cell Mol Biol. 2016; 55(3):387-94. PMC: 5023029. DOI: 10.1165/rcmb.2015-0405OC. View

Pickles R, DeVincenzo J . Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis. J Pathol. 2014; 235(2):266-76. PMC: 5638117. DOI: 10.1002/path.4462. View

Zheng M, Wakim L . Tissue resident memory T cells in the respiratory tract. Mucosal Immunol. 2021; 15(3):379-388. PMC: 8526531. DOI: 10.1038/s41385-021-00461-z. View

Makris S, Bajorek M, Culley F, Goritzka M, Johansson C . Alveolar Macrophages Can Control Respiratory Syncytial Virus Infection in the Absence of Type I Interferons. J Innate Immun. 2016; 8(5):452-63. PMC: 5322584. DOI: 10.1159/000446824. View

Ma Y, Zhang Y, Zhu L . Role of neutrophils in acute viral infection. Immun Inflamm Dis. 2021; 9(4):1186-1196. PMC: 8589350. DOI: 10.1002/iid3.500. View

Midulla F, Huang Y, Gilbert I, Cirino N, McFadden Jr E, Panuska J . Respiratory syncytial virus infection of human cord and adult blood monocytes and alveolar macrophages. Am Rev Respir Dis. 1989; 140(3):771-7. DOI: 10.1164/ajrccm/140.3.771. View

10.

Stuart A, Virta M, Williams K, Seppa I, Hartvickson R, Greenland M . Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months. J Infect Dis. 2022; 227(1):71-82. PMC: 9796164. DOI: 10.1093/infdis/jiac407. View

11.

Schijf M, Lukens M, Kruijsen D, Van Uden N, Garssen J, Coenjaerts F . Respiratory syncytial virus induced type I IFN production by pDC is regulated by RSV-infected airway epithelial cells, RSV-exposed monocytes and virus specific antibodies. PLoS One. 2013; 8(11):e81695. PMC: 3841124. DOI: 10.1371/journal.pone.0081695. View

12.

Christiaansen A, Syed M, Ten Eyck P, Hartwig S, Durairaj L, Kamath S . Altered Treg and cytokine responses in RSV-infected infants. Pediatr Res. 2016; 80(5):702-709. PMC: 6215710. DOI: 10.1038/pr.2016.130. View

13.

Waris M, Tsou C, Erdman D, Zaki S, Anderson L . Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol. 1996; 70(5):2852-60. PMC: 190142. DOI: 10.1128/JVI.70.5.2852-2860.1996. View

14.

CHANOCK R, Roizman B, Myers R . Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg. 1957; 66(3):281-90. DOI: 10.1093/oxfordjournals.aje.a119901. View

15.

Ostler T, Davidson W, Ehl S . Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma. Eur J Immunol. 2002; 32(8):2117-23. DOI: 10.1002/1521-4141(200208)32:8<2117::AID-IMMU2117>3.0.CO;2-C. View

16.

Baxter D . Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007; 57(8):552-6. DOI: 10.1093/occmed/kqm110. View

17.

Loo Y, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L . Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol. 2007; 82(1):335-45. PMC: 2224404. DOI: 10.1128/JVI.01080-07. View

18.

Ha B, Chirkova T, Boukhvalova M, Sun H, Walsh E, Anderson C . Mutation of Respiratory Syncytial Virus G Protein's CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells. Vaccines (Basel). 2019; 7(3. PMC: 6789749. DOI: 10.3390/vaccines7030069. View

19.

Casola A, Saito T, Alam R, Crowe S, Mei F, Ogra P . Cell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J Virol. 1998; 72(6):4756-64. PMC: 110009. DOI: 10.1128/JVI.72.6.4756-4764.1998. View

20.

Bataki E, Evans G, Everard M . Respiratory syncytial virus and neutrophil activation. Clin Exp Immunol. 2005; 140(3):470-7. PMC: 1809401. DOI: 10.1111/j.1365-2249.2005.02780.x. View